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Annexin A2 antibodies but not inhibitors of
the annexin A2 heterotetramer impair
productive HIV-1 infection of macrophages
in vitro
Andrew W. Woodham1, Adriana M. Sanna2,3, Julia R. Taylor4, Joseph G. Skeate4, Diane M. Da Silva5,
Lodewijk V. Dekker6 and W. Martin Kast4*
Abstract
During sexual transmission of human immunodeficiency virus (HIV), macrophages are initial targets for HIV infection.
Secretory leukocyte protease inhibitor (SLPI) has been shown to protect against HIV infection of macrophages
through interactions with annexin A2 (A2), which is found on the macrophage cell surface as a heterotetramer (A2t)
consisting of A2 and S100A10. Therefore, we investigated potential protein-protein interactions between A2 and
HIV-1 gp120 through a series of co-immunoprecipitation assays and a single molecule pulldown (SiMPull)
technique. Additionally, inhibitors of A2t (A2ti) that target the interaction between A2 and S100A10 were tested for
their ability to impair productive HIV-1 infection of macrophages. Our data suggest that interactions between HIV-1
gp120 and A2 exist, though this interaction may be indirect. Furthermore, an anti-A2 antibody impaired HIV-1
particle production in macrophages in vitro, whereas A2ti did not indicating that annexin A2 may promote HIV-1
infection of macrophages in its monomeric rather than tetrameric form.
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Introduction
During sexual transmission of human immunodeficiency
virus (HIV), macrophages of the cervical, anal, and
foreskin epithelium are among the first immune cells to
encounter the virus, which makes them initial targets for
HIV infection [1, 2]. It is well established that secretory
leukocyte protease inhibitor (SLPI), a protein found in
high concentrations in mucosal fluids, protects against
HIV-1 infection of macrophages independent of its
anti-protease activity [3, 4]. Moreover, when the host-
cell membrane constituent phospholipid phosphatidyl-
serine (PS) is incorporated into the viral envelope during
the budding process, it acts as a cofactor for HIV-1
infection of macrophages [5]. The ability of host-derived
PS to influence HIV-1 infection led to the prediction
that an unknown factor on target-cell membranes
facilitated viral binding and/or fusion through PS. It was
later revealed that SLPI directly interacted with annexin
A2 (A2), a PS-binding moiety, and that SLPI could disrupt
the interaction between A2 and PS on the HIV-1 envelope
to prevent infection in vitro [6] (also see Fig. 1d).
Additionally, antibodies against A2 or RNA silencing of
A2 significantly inhibited HIV-1 infection similar to that
of SLPI. It was also shown that A2 is involved in HIV-1
replication in monocyte-derived macrophages (MDMs)
[7], and that HIV-1 produced from MDMs that had been
treated with A2 siRNA exhibited decreased infectivity [8].
Generally, HIV-1 infects macrophages through the
canonical CD4 receptor CCR5 coreceptor pathway [2, 9],
though numerous cofactors can affect the efficiency of this
process and the rate of infection [5, 6]. Entry inhibitors,
such as the CCR5 antagonist maraviroc [10], often lead to
the emergence of resistant HIV-1 strains that can use
alternative pathways [9]. Moreover, alternative pathways
of HIV-1 infection are likely to differ in macrophages
and CD4+ T cells as they express different membrane
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components such as PS and A2, which are found on
the macrophage cell membrane but not on viable T cells
[4, 7]. A2 can be found on the cell surface as a heterotetra-
mer (A2t) consisting of two A2 monomers and an
S100A10 dimer [11], which are co-expressed by macro-
phages [7]. Additionally, data from the HIV-1 Human
Interaction Database from the National Center for
Biotechnology Information (NCBI) suggests that there
may be interactions between HIV-1 gp120 and host A2
[12], though direct evidence is lacking. Recently, our
collaborators developed triazole-based small molecule
inhibitors of A2t (A2ti) that specifically disrupt the
interaction between A2 and S100A10 [13], and we showed
that these small molecules block infection of the A2t-
utilizing human papillomavirus type 16 (HPV16) [14], but
have yet to be explored in the context of HIV. While A2
has already been implicated in HIV-1 infection of macro-
phages [6, 15], it is not understood if A2t acts as a cofactor
for infection. Therefore, the goals of the current study
were to investigate potential protein-protein interactions
between A2 and the HIV-1 envelope protein gp120, and
the ability of A2ti to inhibit HIV-1 infection of macro-
phages in vitro.
Methods
HEK293T cells maintained in in DMEM with L-
glutamine (Lonza, Walkersville, MD, USA), 10% FBS,
and 1% sodium pyruvate were transfected at 50–75%
confluence with the HIV-1JR-CSF plasmid using the
Calcium Phosphate Transfection Kit (Invitrogen, Life
technologies) according to manufacturer instructions.
Supernatants containing HIV-1 (viral inoculum) were
harvested after 72 h, filtered through 0.45 μM filters,
and titered using the GHOST-indicator cell line as
previously described [16]. Monocytes were isolated from
total peripheral blood mononuclear cells (PBMC) via the
EasySep negative selection Human Monocyte Enrich-
ment kit (STEMCELL technologies) according to manu-
facturer instructions. Isolated monocytes were then used
to derive MDMs via 7-day incubation with 1000 U/mL
Fig. 1 A2 from macrophage lysates is captured on HIV-1 gp120-coated SiMPull slides. Lysis buffer (a) or macrophage cell lysates (b) were flowed onto
SiMPull slides coated with increasing amounts of biotinylated gp120, and the number of captured complexes (c) were detected following staining
with a rabbit anti-A2 antibody and an anti-rabbit 568-conjugated secondary antibody using TIRF microscopy, where each white dot represents one
protein-protein complex (scale bar = 5 μm). Controls included no gp120 and no lysate. Data are presented as the means ± SD of five fields of view of a
representative example of an experiment performed three times. *p < 0.05 **p < 0.01 as determined by a one-way ANOVA followed by a Kruskal-Wallis
multiple comparisons test against the no gp120 control group. d In a separate experiment, lysates were flowed onto SiMPull slides coated with an
anti-A2 antibody, and captured complexes were detected with mouse anti-S100A10 or anti-SLPI primary antibodies and an anti-mouse 568-conjugated
secondary antibody. ***p< 0.001 as determined by an unpaired two-tailed Student’s T-test against the no capture control group
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granulocyte-macrophage colony-stimulating factor (GM-
CSF) (Leukine, Sanofi-Aventis, Bridgewater, NJ, USA) as
previously described [17], and were confirmed as CD11c
+CD14−CD4lowCCR5+A2+S100A10+ (data not shown).
Recombinant A2 and S100A10 proteins were gifts from
Ralf Langen [18], and recombinant purified HIV-1
gp120 biotin was purchased from Immune Technology
(New York, NY, USA). A2ti were synthesized as de-
scribed [13].
Results
Through a series of enzyme-linked immunosorbent as-
says (ELISA) and co-immunoprecipitation (co-IP) assays,
we investigated whether A2 directly interacts with the
primary HIV-1 envelope protein gp120. Following
published procedures that we utilized for the evaluation
of A2 interactions with HPV16 [18], we found that
recombinant gp120 was not able to bind to purified A2
or S100A10 when measured via ELISA, and that gp120
incubated with macrophages was unable to co-IP with
A2 (data not shown). However, in addition to traditional
co-IP assays, we used a highly-sensitive single molecule
pulldown (SiMPull) technique that combines classical
pulldown methodology with single molecule fluores-
cence imaging [19]. We found that when biotinylated
gp120 (1 μg/mL) was captured onto SiMPull slides as a
bait protein via NeutrAvidin [19], and macrophage
lysates (protein concentration 0.5 μg/mL) were then
added, A2-gp120 complexes were detected with a rabbit
anti-A2 antibody (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) followed by an anti-rabbit 568-
conjugated secondary antibody (Abcam, Cambridge,
MA, USA) using total internal reflection fluorescence
(TIRF) microscopy. Max gp120 binding to the slides
(100%) was determined as the amount of gp120 added at
which no more could be detected directly with an anti-
gp120 antibody (Immune Technology). The slides were
washed after each step to remove unbound gp120,
proteins in the lysate, and detection antibodies. The
maximum number of A2-gp120 complexes detected was
approximately 50% of those detected for A2-S100A10 or
A2-SLPI complexes detected in control experiments
with an anti-A2 capture antibody (BD Bioscience) and
S100A10 (BD Bioscience) and SLPI (R&D Systems)
detection antibodies, but was 3-fold higher than back-
ground levels (Fig. 1c and d). These results indicate that
A2 from macrophage lysates interacts with gp120 in the
absence of other viral proteins, though it is possible that
this interaction is indirect and is mediated by other
binding partners present in macrophage lysate (Fig. 1).
Next, we validated the effects of an antibody against
the N-terminus of A2 on productive HIV-1 infection of
macrophages [6]. Macrophages were pre-treated with
the anti-A2 antibody (Santa Cruz), or maraviroc (NIH
Fig. 2 in vitro HIV-1 infection of macrophages following treatment with A2ti, anti-A2 antibody, or maraviroc. a Structures and reported IC50 values
of the three triazole-based A2ti tested [13]. b Macrophages were treated with different A2ti (25 or 50 μM), an anti-A2 antibody (25 μg/mL), or
maraviroc (25 μg/mL) prior to exposure to HIV-1JR-CSF (MOI = 1). After 24 h, the supernatants were collected and the relative amount of the
HIV-1 capsid protein p24 (pg/mL) was measured via ELISA. Controls included uninfected, HIV only, heat-inactivated virus (H.I. HIV), and DMSO
at a concentration matched to that of 50 μM A2ti. Data are presented as the means ± SD of three independent experiments. **p < 0.01 and
***p < 0.001 as determined by unpaired two-tailed Student’s t-tests compared to the HIV only group. c HaCaT cells were left untreated or
treated with 50 μM A2ti-1. The following day cells were infected with GFP-plasmid-containing HPV16 pseudovirions (PsV). GFP-positive cells were
measured after 48 h by flow cytometry. The mean percentage ± SD of infected cells normalized to the untreated group from a representative experiment
performed in triplicate is presented. **p< 0.01 as determined by unpaired two-tailed Student’s t-test compared to the untreated group
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AIDS Research and Reference Reagent Program) for 4 h
prior to the addition of HIV-1JR-CSF (MOI = 1), and
infection was measured via HIV-1 p24 ELISA (ABL,
Kensington, MD, USA) following published procedures
[6]. Maraviroc efficiently impaired HIV-1 particle pro-
duction as demonstrated by a three-fold reduction in
p24 detection, which was expected as maraviroc is a
CCR5 antagonist known to block HIV-1 infection [10].
The antibody against the N-terminus of A2 (Santa Cruz)
also effectively inhibited HIV-1 particle production by
macrophages as efficiently as maraviroc at the same con-
centration (Fig. 2b), indicating that A2 is involved in
productive HIV infection of macrophages, which is in
agreement with previous results [6]. To assess whether
A2 is functional as the A2t heterotetramer or as the A2
monomer in HIV infection, we next determined the
effects of three different A2ti that we previously devel-
oped, two of which had half maximal inhibitory concen-
tration (IC50) values in the low μM range, and one that
was chemically analogous, but had a much higher IC50
value as a control (Fig. 2a) [13]. We found that viral load
as measured by p24 levels did not decrease with any of
the A2ti, even at concentrations well above the reported
IC50 values for the two more potent compounds,
compared to that of the untreated group (Fig. 2b). How-
ever, in agreement with our previous results and following
our published procedures [14], A2ti were able to effect-
ively block A2t-utlizing HPV16 infection of HaCaT
epithelial cells, serving as a positive control for A2ti activ-
ity (Fig. 2c, with data for other A2ti available in [14]).
Discussion
In summary, an anti-A2 antibody targeting the N-
terminus of A2 successfully blocked productive HIV-1 in-
fection of macrophages in vitro, but A2t-targeting drugs
did not, indicating that A2 may promote HIV-1 infection
of macrophages in its monomeric form. This mechanism
is different from HPV infection, which involves the
heterotetrameric form of A2 [18]. Additionally, the highly-
sensitive SiMPull assay demonstrated that immobilized
HIV-1 gp120 captured A2 from macrophage lysates.
However, this interaction was not robust enough to detect
via standard co-IP techniques, and may be indirectly
mediated by unidentified cellular factors. Thus, it is
possible that other factors interact with gp120 and A2,
and these interactions may be blocked by anti-A2 anti-
bodies. As HIV-1 entry inhibitors function to prevent
initial or ongoing spread of infection while the current
standards of care largely target viral enzymes to which
HIV-1 resistance continues to emerge [20], novel entry
inhibitors are of great interest, though future research is
required to determine if monomeric A2 is a viable target
for such approaches.
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